High Purity Pharmaceutical Raw Materials CAS 856867-55-5 Tedizolid Phosphate

High Purity Pharmaceutical Raw Materials CAS 856867-55-5 Tedizolid Phosphate

Product Description

Tedizolid is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).

Tedizolid has been approved by the U.S Food and Drug Administration on June 20, 2014, for the treatment of acute bacterial Skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains, MRSA, and methicillin-susceptible strains), various Streptococcus species (S. pyogenes, S. agalactiae, and S. anginosus group including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis. Tedizolid is a second-generation oxazolidinone derivative that is 4-to-16-fold more potent against staphylococci and enterococci compared to linezolid.

 Quick Details 

Product Name: High Purity Tedizolid Phosphate

Other Name: 

Tedizolid phosphate;

TR-701 FA;

Torezolid phosphate;

[(5R)-3-[3-fluoro-4-[6-(2-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate;

UNII-O7DRJ6R4DW;

CAS: 856867-55-5

MF: C17H16FN6O6P

MW: 450.31800

Application: 

Advantages: